{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T04:20:09Z","timestamp":1778991609495,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor that is composed of mononuclear stroma cells, scattered macrophages, and multinucleated osteoclast-like giant cells which cause pathologic osteolysis. The stroma cells represent the neoplastic population of the tumor and are characterized by the <jats:italic>H3F3A<\/jats:italic> mutation G34W. This point mutation is regarded as the driver mutation of GCTB. We have established three new stable <jats:italic>H3F3A<\/jats:italic> mutated GCTB cell lines: U-GCT1, U-GCT2, and U-GCT3M. MK-1775 is a Wee1-kinase inhibitor which has been used for blocking of sarcoma growth. In the cell lines we detected Wee1, Cdk1, Cyclin B1, H3K36me3, and Rrm2 as members of the Wee1 pathway. We analyzed the effect of MK-1775 and gemcitabine, alone and in combination, on the growth of the cell lines. The cell lines showed a significant reduction in cell proliferation when treated with MK-1775 or gemcitabine. The combination of both agents led to a further significant reduction in cell proliferation compared to the single agents. Immunohistochemical analysis of 13 GCTB samples revealed that Wee1 and downstream-relevant members are present in GCTB tissue samples. Overall, our work offers valuable new tools for GCTB studies and presents a description of novel biomarkers and molecular targeting strategies.<\/jats:p>","DOI":"10.1038\/s41598-019-42611-1","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T10:03:39Z","timestamp":1556013819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway"],"prefix":"10.1038","volume":"9","author":[{"given":"Christoph","family":"L\u00fcbbeh\u00fcsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-6350","authenticated-orcid":false,"given":"Julian","family":"L\u00fcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Seeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Mellert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Marienfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"von Baer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Schultheiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F. E.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"42611_CR1","unstructured":"Athanasou, N. A., Bansal, M. & Forsyth, R. In WHO Classification of Tumours of Soft Tissue and Bone (eds Fletcher, C. D. M., Bridge, J. A., Hogendoorn, P. C. W. & Mertens, F.) 321\u2013324 (IARC Press, Lyon; France, 2013)."},{"key":"42611_CR2","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","volume":"473","author":"LA Aponte-Tinao","year":"2015","unstructured":"Aponte-Tinao, L. A., Piuzzi, N. S., Roitman, P. & Farfalli, G. L. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab. Clin. Orthop. Relat. Res. 473, 3050\u20133055 (2015).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"42611_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s002560050230","volume":"26","author":"EW Brien","year":"1997","unstructured":"Brien, E. W. et al. Benign giant cell tumor of bone with osteosarcomatous transformation (\u201cdedifferentiated\u201d primary malignant GCT): report of two cases. Skeletal Radiol. 26, 246\u2013255 (1997).","journal-title":"Skeletal Radiol."},{"key":"42611_CR4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/ng.2814","volume":"45","author":"S Behjati","year":"2013","unstructured":"Behjati, S. et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat. Genet. 45, 1479\u20131482 (2013).","journal-title":"Nat. Genet."},{"key":"42611_CR5","first-page":"297","volume":"16","author":"MH Zheng","year":"2001","unstructured":"Zheng, M. H. et al. The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol. Histopathol. 16, 297\u2013307 (2001).","journal-title":"Histol. Histopathol."},{"key":"42611_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1309\/BPET-F2PE-P2BD-J3P3","volume":"117","author":"S Roux","year":"2002","unstructured":"Roux, S. et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am. J. Clin. Pathol. 117, 210\u2013216 (2002).","journal-title":"Am. J. Clin. Pathol."},{"key":"42611_CR7","first-page":"2","volume":"4","author":"A Sobti","year":"2016","unstructured":"Sobti, A., Agrawal, P., Agarwala, S. & Agarwal, M. Giant Cell Tumor of Bone - An Overview. Arch. Bone Jt. Surg. 4, 2\u20139 (2016).","journal-title":"Arch. Bone Jt. Surg."},{"key":"42611_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11999-010-1501-7","volume":"469","author":"FM Klenke","year":"2011","unstructured":"Klenke, F. M., Wenger, D. E., Inwards, C. Y., Rose, P. S. & Sim, F. H. Giant cell tumor of bone: risk factors for recurrence. Clin. Orthop. Relat. Res. 469, 591\u2013599 (2011).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"42611_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"Chawla, S. et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. The Lancet Oncology 14, 901\u2013908 (2013).","journal-title":"The Lancet Oncology"},{"key":"42611_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1155\/2015\/767198","volume":"2015","author":"CJ Broehm","year":"2015","unstructured":"Broehm, C. J., Garbrecht, E. L., Wood, J. & Bocklage, T. Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab. Case Rep. Med. 2015, 6 (2015).","journal-title":"Case Rep. Med."},{"issue":"11","key":"42611_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/jjco\/hyx112","volume":"47","author":"S Tsukamoto","year":"2017","unstructured":"Tsukamoto, S. et al. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol. 47(11), 1090\u20131096 (2017).","journal-title":"Jpn J Clin Oncol."},{"key":"42611_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister, S. X. et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer. Cell. 28, 557\u2013568 (2015).","journal-title":"Cancer. Cell."},{"key":"42611_CR13","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai, H. et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer. Ther. 8, 2992\u20133000 (2009).","journal-title":"Mol. Cancer. Ther."},{"key":"42611_CR14","doi-asserted-by":"publisher","first-page":"e38254","DOI":"10.1371\/journal.pone.0038254","volume":"7","author":"GI Magnussen","year":"2012","unstructured":"Magnussen, G. I. et al. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 7, e38254 (2012).","journal-title":"PLoS One"},{"key":"42611_CR15","doi-asserted-by":"publisher","first-page":"e57523","DOI":"10.1371\/journal.pone.0057523","volume":"8","author":"JM Kreahling","year":"2013","unstructured":"Kreahling, J. M. et al. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One 8, e57523 (2013).","journal-title":"PLoS One"},{"key":"42611_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1535-7163.MCT-11-0529","volume":"11","author":"JM Kreahling","year":"2012","unstructured":"Kreahling, J. M. et al. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol. Cancer. Ther. 11, 174\u2013182 (2012).","journal-title":"Mol. Cancer. Ther."},{"key":"42611_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0092-8674(93)80048-J","volume":"74","author":"R Heald","year":"1993","unstructured":"Heald, R., McLoughlin, M. & McKeon, F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 74, 463\u2013474 (1993).","journal-title":"Cell"},{"key":"42611_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4781(01)00204-4","volume":"1519","author":"VA Smits","year":"2001","unstructured":"Smits, V. A. & Medema, R. H. Checking out the G(2)\/M transition. Biochim. Biophys. Acta 1519, 1\u201312 (2001).","journal-title":"Biochim. Biophys. Acta"},{"key":"42611_CR19","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","volume":"17","author":"DW Hamer","year":"2011","unstructured":"Hamer, D. W. et al. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 17, 4200\u20134207 (2011).","journal-title":"Clin. Cancer Res."},{"key":"42611_CR20","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/sj.onc.1204252","volume":"20","author":"WR Taylor","year":"2001","unstructured":"Taylor, W. R. & Stark, G. R. Regulation of the G2\/M transition by p53. Oncogene 20, 1803\u20131815 (2001).","journal-title":"Oncogene"},{"key":"42611_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2174\/157488410791498824","volume":"5","author":"S Leijen","year":"2010","unstructured":"Leijen, S., Beijnen, J. H. & Schellens, J. H. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr. Clin. Pharmacol. 5, 186\u2013191 (2010).","journal-title":"Curr. Clin. Pharmacol."},{"key":"42611_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","volume":"39","author":"AH Cleven","year":"2015","unstructured":"Cleven, A. H. et al. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. Am. J. Surg. Pathol. 39, 1576\u20131583 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"42611_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-156","volume":"11","author":"J PosthumaDeBoer","year":"2011","unstructured":"PosthumaDeBoer, J. et al. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 11, 156 (2011).","journal-title":"BMC Cancer"},{"key":"42611_CR24","doi-asserted-by":"publisher","first-page":"e5120","DOI":"10.1371\/journal.pone.0005120","volume":"4","author":"E Iorns","year":"2009","unstructured":"Iorns, E. et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 4, e5120 (2009).","journal-title":"PLoS One"},{"key":"42611_CR25","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1200\/jco.2010.28.15_suppl.3067","volume":"28","author":"S Leijen","year":"2010","unstructured":"Leijen, S. et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. JCO 28, 3067\u20133067 (2010).","journal-title":"JCO"},{"key":"42611_CR26","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/07328318908054215","volume":"8","author":"W Plunkett","year":"1989","unstructured":"Plunkett, W. et al. 2\u2032,2\u2032-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells. Nucleosides and Nucleotides 8, 775\u2013785 (1989).","journal-title":"Nucleosides and Nucleotides"},{"key":"42611_CR27","first-page":"567","volume":"38","author":"V Heinemann","year":"1990","unstructured":"Heinemann, V. et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2032,2\u2032-difluorodeoxycytidine. Mol. Pharmacol. 38, 567\u2013572 (1990).","journal-title":"Mol. Pharmacol."},{"key":"42611_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/his.13190","volume":"71","author":"J L\u00fcke","year":"2017","unstructured":"L\u00fcke, J. et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology 71, 125\u2013133 (2017).","journal-title":"Histopathology"},{"key":"42611_CR29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1359\/jbmr.2000.15.4.640","volume":"15","author":"GJ Atkins","year":"2000","unstructured":"Atkins, G. J. et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 15, 640\u2013649 (2000).","journal-title":"J. Bone Miner. Res."},{"key":"42611_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.440","volume":"5","author":"L Liu","year":"2014","unstructured":"Liu, L. et al. Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib. Cell. Death Dis. 5, e1471 (2014).","journal-title":"Cell. Death Dis."},{"key":"42611_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/neuonc\/not220","volume":"16","author":"S Mueller","year":"2014","unstructured":"Mueller, S. et al. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro Oncol. 16, 352\u2013360 (2014).","journal-title":"Neuro Oncol."},{"issue":"6","key":"42611_CR32","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.3892\/ol.2017.5984","volume":"13","author":"X- Ge","year":"2017","unstructured":"Ge, X.- et al. Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. Oncology Letters 13(6), 4341\u20134348 (2017).","journal-title":"Oncology Letters"},{"key":"42611_CR33","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1073\/pnas.0609299104","volume":"104","author":"TM Kiviharju-af Hallstrom","year":"2007","unstructured":"Kiviharju-af Hallstrom, T. M. et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. USA 104, 7211\u20137216 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"42611_CR34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/gcc.20656","volume":"48","author":"L Moskovszky","year":"2009","unstructured":"Moskovszky, L. et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer 48, 468\u2013479 (2009).","journal-title":"Genes Chromosomes Cancer"},{"key":"42611_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/1097-0142(19950201)75:3<806::AID-CNCR2820750310>3.0.CO;2-S","volume":"75","author":"K Scotlandi","year":"1995","unstructured":"Scotlandi, K. et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer 75, 806\u2013814 (1995).","journal-title":"Cancer"},{"key":"42611_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/01.MP.0000057235.65327.40","volume":"16","author":"A Kauzman","year":"2003","unstructured":"Kauzman, A. et al. Cyclin alterations in giant cell tumor of bone. Mod. Pathol. 16, 210\u2013218 (2003).","journal-title":"Mod. Pathol."},{"key":"42611_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1083\/jcb.141.4.875","volume":"141","author":"P Jin","year":"1998","unstructured":"Jin, P., Hardy, S. & Morgan, D. O. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J. Cell Biol. 141, 875\u2013885 (1998).","journal-title":"J. Cell Biol."},{"key":"42611_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s002800050027","volume":"45","author":"O Merimsky","year":"2000","unstructured":"Merimsky, O. et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother. Pharmacol. 45, 177\u2013181 (2000).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"42611_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-2407-11-241","volume":"11","author":"M Balke","year":"2011","unstructured":"Balke, M. et al. A short-term in vivo model for giant cell tumor of bone. BMC Cancer 11, 241\u2013241 (2011).","journal-title":"BMC Cancer"},{"key":"42611_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/PAS.0000000000000506","volume":"40","author":"J Wojcik","year":"2016","unstructured":"Wojcik, J. et al. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone. Am. J. Surg. Pathol. 40, 72\u201380 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"42611_CR41","first-page":"2032-017","volume":"7","author":"D Jager","year":"2017","unstructured":"Jager, D. et al. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. Sci. Rep. 7, 2032-017\u201302174-5 (2017).","journal-title":"Sci. Rep."},{"key":"42611_CR42","first-page":"4537","volume":"9","author":"J An","year":"2003","unstructured":"An, J. et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin. Cancer Res. 9, 4537\u20134545 (2003).","journal-title":"Clin. Cancer Res."},{"key":"42611_CR43","unstructured":"Zentrale Ethikkommission bei der Bundes\u00e4rztekammer. Mitteilungen: Die (Weiter-)Verwendung von menschlichen K\u00f6rpermaterialien f\u00fcr Zwecke medizinischer Forschung. Dtsch \u00c4rztebl International, A-1632 (2003)."},{"key":"42611_CR44","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","DOI":"10.1001\/jama.2013.281053"},{"key":"42611_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4161\/cc.1.6.257","volume":"1","author":"H Dixon","year":"2002","unstructured":"Dixon, H. & Norbury, C. J. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell. Cycle 1, 362\u2013368 (2002).","journal-title":"Cell. Cycle"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42611-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:59:43Z","timestamp":1671267583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42611-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42611"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42611-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"16 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6458"}}